Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients

類似資料

• Oral Hypoxia–Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG-4592) for the Treatment of Anemia in Patients with CKD
  著者:: Provenzano, Robert, 等
  出版事項: (2016)
• Roxadustat (FG-4592): Correction of Anemia in Incident Dialysis Patients
  著者:: Besarab, Anatole, 等
  出版事項: (2016)
• Oral Hypoxia‐Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG‐4592) for Treatment of Anemia in Chronic Kidney Disease: A Placebo‐Controlled Study of Pharmacokinetic and Pharmacodynamic Profiles in Hemodialysis Patients
  著者:: Provenzano, Robert, 等
  出版事項: (2020)
• Radioprotective effects of roxadustat (FG‐4592) in haematopoietic system
  著者:: Zhang, Pei, 等
  出版事項: (2018)
• Phase 2 studies of oral hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for treatment of anemia in China
  著者:: Chen, Nan, 等
  出版事項: (2017)